Log in
Enquire now
Moderna Therapeutics

Moderna Therapeutics

A biotechnology startup company that develops messenger RNA based therapeutics to treat diseases.

OverviewStructured DataIssuesContributors

Contents

modernatx.com
modernatx.com/en-CA
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Biotechnology
Biotechnology
Healthcare
Healthcare
Infectious disease (medical specialty)
Infectious disease (medical specialty)
Internal medicine
Internal medicine
Cardiology
Cardiology
Engineering
Engineering
Endocrine disease
Endocrine disease
...
Location
United Kingdom
United Kingdom
Cambridge, Massachusetts
Cambridge, Massachusetts
Canada
Canada
United States
United States
Bristol
Bristol
B2X
B2B
B2B
CEO
‌
Stephane Bancel
Stéphane Bancel
Stéphane Bancel
Founder
Kenneth R. Chien
Kenneth R. Chien
Robert S. Langer
Robert S. Langer
‌
Timothy A. Springer
Noubar Afeyan
Noubar Afeyan
Derrick Rossi
Derrick Rossi
AngelList URL
angel.co/moderna-therapeutics
Pitchbook URL
pitchbook.com/profiles.../51074-47
Legal Name
Moderna, Inc.
Parent Organization
Robert S. Langer
Robert S. Langer
Noubar Afeyan
Noubar Afeyan
Legal classification
Private limited company
Private limited company
Delaware
Delaware
0
Date Incorporated
2016
Spinout
Onkaido Therapeutics
Onkaido Therapeutics
Number of Employees (Ranges)
1,001 – 5,000
Email Address
media@modernatx.com
ir@modernatx.com
Phone Number
+16177146500
+12522277013
+18666633762
+12023076990
Number of Employees
830
Full Address
200 Technology Sq Cambridge​, MA, 02139-3578 United States
11Th Floor, Whitefriars, Lewins Mead, Bristol, England, BS1 2NT
CIK Number
1,682,852
Incorporation Reference
11990046
Investors
Abu Dhabi Investment Authority
Abu Dhabi Investment Authority
The Pictet Group
The Pictet Group
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA)
BB Biotech
BB Biotech
Alexion Pharmaceuticals
Alexion Pharmaceuticals
Viking Global Investors
Viking Global Investors
Merck KgAa
Merck KgAa
AstraZeneca
AstraZeneca
...
Founded Date
2010
Fax Number
1-617-649-3910
Total Funding Amount (USD)
2,707,000,000
Latest Funding Round Date
July 26, 2020
Competitors
Avidity Biosciences
Avidity Biosciences
Sputnik V
Sputnik V
R-Zero
R-Zero
Exuma Biotechnology
Exuma Biotechnology
OrphAI Therapeutics
OrphAI Therapeutics
0
Kernal Biologics
Kernal Biologics
Meissa Vaccines
Meissa Vaccines
Arcturus Therapeutics
Arcturus Therapeutics
...
Business Model
Commerce
Stock Symbol
MRNA
Exchange
Nasdaq
Nasdaq
Board of Directors
Stéphane Bancel
Stéphane Bancel
Henri Termeer
Henri Termeer
‌
Elizabeth Tallett
François Nader
François Nader
‌
Stephen Berenson
‌
Sandra Horning
Robert Langer
Robert Langer
Elizabeth Nabel
Elizabeth Nabel
...
CTO
‌
Juan Andres
CFO
‌
David Meline
Former CEO
‌
Stephane Bancel
Key People
Stéphane Bancel
Stéphane Bancel
Robert S. Langer
Robert S. Langer
‌
Stephen Hoge
Paul Sagan
Paul Sagan
Noubar Afeyan
Noubar Afeyan
‌
David Meline
Also Known As
Moderna
Latest Funding Type
‌
Series H round
Latest Postmoney Valuation
2,600,000,000
Patents Assigned (Count)
34
Legal Entity Identifier
549300EI6OKH5K5Q2G380
Wellfound ID
moderna-therapeutics
Technologies Used
CRISPR
CRISPR
Country
United Kingdom
United Kingdom
United States
United States
Headquarters
Cambridge, Massachusetts
Cambridge, Massachusetts

Other attributes

Blog
modernatx.com/media-ce...dia/blogs
Company Operating Status
Active
Owner
Robert S. Langer
Robert S. Langer
AstraZeneca
AstraZeneca
Noubar Afeyan
Noubar Afeyan
Ticker Symbol
MRNA
UKSIC Code
72110
Wikidata ID
Q17081612

Moderna is focused on developing mRNA-based therapies. Their research works to overcome challenges such as delivery of the mRNA into target tissue and cells, evading the immune system and proper recognition and reading of mRNA messages by ribosomes in the cell. The company uses Amazon’s cloud platform to help speed up the process for getting drugs from research to clinical trials.

COVID-19 response

Moderna has a collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) to produce a vaccine against coronavirus to fight the SARS-CoV-2 (2019-nCoV) outbreak. The coronavirus strain has more recently been renamed SARS-CoV-2 with the disease called COVID-19 (coronavirus disease). That funding will cover manufacturing costs for an mRNA vaccine candidate against the new strain of coronavirus. Preclinical tests and a phase 1 study are planned with supported from federal researchers at the National Institute of Allergy and Infectious Diseases (NIAID). In their approach for SARS-CoV-2 (2019-nCoV), Moderna is using the same technique used to produce a cancer vaccine in 40 days.

Moderna is working with Dr. Barney Graham, deputy director of the Vaccine Research Center at the NIH on SARS-CoV-2 (2019-nCoV) vaccine development. Graham’s research team used sequence information of the 2019-nCoV posted by Chinese scientists on a public database to identify a region of the genetic code to be used to generate a vaccine. The scientists focused on the spike protein, which recognizes receptors or entry points on the host cell. A template for the SARS vaccine was used with the SARS-CoV-2 (2019-nCoV) genetic code swapped in. The sequence was sent to Moderna to make synthetic mRNA for production of protein in order to generate antibodies that target the spike protein.

mRNA-1273 entered Phase I trials on March 3, 2020 and are expected to conclude on June 1, 2021.

On March 16, 2020, the mRNA vaccine called mRNA-1273 began being injected into volunteers in a clinical trial performed by Kaiser Permanente Washington Health Research Institute (KPWHRI).

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

How effective is the Moderna vaccine against Omicron?

https://www.youtube.com/watch?v=SPvqfJR6Wlo

Web

December 16, 2021

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19) - Full Text View - ClinicalTrials.gov

https://clinicaltrials.gov/ct2/show/NCT04283461?term=vaccine&cond=covid-19&draw=2

Web

References

Find more companies like Moderna Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.